Progress in Medicinal Chemistry: Volume 44

F.D. King · G. Lawton

មេសា 2006 · Progress in Medicinal Chemistry សៀវភៅទី 44 · Elsevier

សៀវភៅអេឡិចត្រូនិច

404

ទំព័រ

មានសិទ្ធិ

ការវាយតម្លៃ និងមតិវាយតម្លៃមិនត្រូវបានផ្ទៀងផ្ទាត់ទេ ស្វែងយល់បន្ថែម

អំពីសៀវភៅអេឡិចត្រូនិកនេះ

The perceived lack of drug discovery productivity in recent times has led to much debate in the pharmaceutical/biotechnology industry as escalating R&D costs are not being matched by increased output. Few observers doubt that selecting the right targets, ie those which are critical to disease pathology and are 'druggable', is the best starting point for improved productivity.The seven chapters of this volume describe recent progress towards drugs acting at a range of 'druggable' targets. One chapter addresses kinases, one covers an ion channel, two proteases are featured and three of the chapters cover G-protein coupled receptors, which has historically perhaps been the most fruitful area for medicinal chemists.*Presents the latest research in the field of drug discovery *Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect

អំពីអ្នកនិពន្ធ

Dr Geoff Lawton has extensive experience in new medicine discovery across many therapeutic areas in both large and small companies and is a co-inventor of a marketed drug (Cilazapril). He is a former Director of Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. He was for five years the research member of a global therapy area strategy planning team for inflammatory diseases, aligning research with the clinical development and marketing parts of the business.From 2003 to 2007 he was founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines. Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant for a number small and medium sized biotech companies, CROs, VCs, academic groups and medical research charities. Geoff serves on the Board of Antabio, a French biotech company developing tomorrow’s antibacterial drugs.He is a founder of INMedD, a new medicines discovery social enterprise.

វាយតម្លៃសៀវភៅអេឡិចត្រូនិកនេះ

ប្រាប់យើងអំពីការយល់ឃើញរបស់អ្នក។

អានព័ត៌មាន

ទូរសព្ទឆ្លាតវៃ និងថេប្លេត

ដំឡើងកម្មវិធី Google Play Books សម្រាប់ Android និង iPad/iPhone ។ វាធ្វើសមកាលកម្មដោយស្វ័យប្រវត្តិជាមួយគណនីរបស់អ្នក និងអនុញ្ញាតឱ្យអ្នកអានពេលមានអ៊ីនធឺណិត ឬគ្មានអ៊ីនធឺណិតនៅគ្រប់ទីកន្លែង។

កុំព្យូទ័រយួរដៃ និងកុំព្យូទ័រ

អ្នកអាចស្ដាប់សៀវភៅជាសំឡេងដែលបានទិញនៅក្នុង Google Play ដោយប្រើកម្មវិធីរុករកតាមអ៊ីនធឺណិតក្នុងកុំព្យូទ័ររបស់អ្នក។

eReaders និងឧបករណ៍ផ្សេងទៀត

ដើម្បីអាននៅលើឧបករណ៍ e-ink ដូចជាឧបករណ៍អានសៀវភៅអេឡិចត្រូនិក Kobo អ្នកនឹងត្រូវទាញយកឯកសារ ហើយផ្ទេរវាទៅឧបករណ៍របស់អ្នក។ សូមអនុវត្តតាមការណែនាំលម្អិតរបស់មជ្ឈមណ្ឌលជំនួយ ដើម្បីផ្ទេរឯកសារទៅឧបករណ៍អានសៀវភៅអេឡិចត្រូនិកដែលស្គាល់។

រាយការណ៍អំពីខ្លឹមសារខុសច្បាប់